Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 210

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

Open access
Chaib, Imane, Karachaliou, Niki, Pilotto, Sara, Codony Servat, Jordi, Cai, Xueting, Li, Xuefei, Drozdowskyj, Ana, Servat, Carles Codony, Yang, Jie, Hu, Chunping, Cardona, Andres Felipe, Vivanco, Guillermo Lopez, Vergnenegre, Alain, Sanchez, Jose Miguel, Provencio, Mariano, de Marinis, Filippo, Passaro, Antonio, Carcereny, Enric, Reguart, Noemi, Campelo, Charo Garcia, Teixido, Cristina, Sperduti, Isabella, Rodriguez, Sonia, Lazzari, Chiara, Verlicchi, Alberto, de Aguirre, Itziar, Queralt, Cristina, Wei, Jia, Estrada, Roger, de la Bellacasa, Raimon Puig, Ramirez, Jose Luis, Jacobsen, Kirstine, Ditzel, Henrik J., Santarpia, Mariacarmela, Viteri, Santiago, Molina, Miguel Angel, Zhou, Caicun, Cao, Peng, Ma, Patrick C., Bivona, Trever G., Rosell, Rafael·2017·JNCI: Journal of the National Cancer Institute

Abstract

Background: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC) is limited by adaptive activation of cell survival signals. We hypothesized that both signal transducer and activator of transcription 3 (STAT3) and Src-YES-associated protein 1 (YAP1) signaling are dually activated during EGFR TKI treatment to limit therapeutic response. Methods: We used MTT and clonogenic assays, immunoblotting, and quantitative polymerase chain reaction to evaluate the efficacy of EGFR TKI alone and in combination with STAT3 and Src inhibition in three EGFR-mutant NSCLC cell lines. The Chou-Talalay method was used for the quantitative determination of drug interaction. We examined tumor growth inhibition in one EGFR-mutant NSCLC xenograft model (n = 4 mice per group). STAT3 and YAP1 expression was evaluated in tumors from 119 EGFR-mutant NSCLC patients (64 in an initial cohort and 55 in a validation cohort) by quantitative polymerase chain reaction. Kaplan-Meier and Cox regression analyses were used to assess the correlation between survival and gene expression. All statistical tests were two-sided. Results: We discovered that lung cancer cells survive initial EGFR inhibitor treatment through activation of not only STAT3 but also Src-YAP1 signaling. Cotargeting EGFR, STAT3, and Src was synergistic in two EGFR-mutant NSCLC cell lines with a combination index of 0.59 (95% confidence interval [CI] = 0.54 to 0.63) for the PC-9 and 0.59 (95% CI = 0.54 to 0.63) for the H1975 cell line. High expression of STAT3 or YAP1 predicted worse progression-free survival (hazard ratio [HR] = 3.02, 95% CI = 1.54 to 5.93, P = .001, and HR = 2.57, 95% CI = 1.30 to 5.09, P = .007, respectively) in an initial cohort of 64 EGFR-mutant NSCLC patients treated with firstline EGFR TKIs. Similar results were observed in a validation cohort. Conclusions: Our study uncovers a coordinated signaling network centered on both STAT3 and Src-YAP signaling that limits targeted therapy response in lung cancer and identifies an unforeseen rational upfront polytherapy strategy to minimize residual disease and enhance clinical outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djx014

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 210

Metadata

Authors
Chaib, I., Karachaliou, N., Pilotto, S., Codony Servat, J., Cai, X., Li, X., Drozdowskyj, A., Servat, C. C., Yang, J., Hu, C., Cardona, A. F., Vivanco, G. L., Vergnenegre, A., Sanchez, J. M., Provencio, M., de Marinis, F., Passaro, A., Carcereny, E., Reguart, N., Campelo, C. G., Teixido, C., Sperduti, I., Rodriguez, S., Lazzari, C., Verlicchi, A., de Aguirre, I., Queralt, C., Wei, J., Estrada, R., de la Bellacasa, R. P., Ramirez, J. L., Jacobsen, K., Ditzel, H. J., Santarpia, M., Viteri, S., Molina, M. A., Zhou, C., Cao, P., Ma, P. C., Bivona, T. G., & Rosell, R.
Venue
JNCI: Journal of the National Cancer Institute
Published
2017-03-31
Volume
109
Issue
9
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2603774629
Cited by
210
References
11
FWCI
24.50
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. https://app.cochat.ai/papers/10.1093/jnci/djx014
The paper
Chaib, I., Karachaliou, N., Pilotto, S., Codony Servat, J., Cai, X., Li, X., Drozdowskyj, A., Servat, C. C., Yang, J., Hu, C., Cardona, A. F., Vivanco, G. L., Vergnenegre, A., Sanchez, J. M., Provencio, M., de Marinis, F., Passaro, A., Carcereny, E., Reguart, N., . . . Rosell, R. (2017). Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djx014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.